HawkEye 360 Raises $416M in NYSE IPO at $2.3B Valuation
HawkEye 360 (NYSE: HAWK) priced at $26, raising $416M. Revenue surged 74% to $118M and EBITDA turned positive as defense-tech satellite demand accelerates.
capital markets
Fed’s Third Rate Hold Drives Yields Toward 2026 Highs
The Fed held rates at 3.5%–3.75% for a third straight meeting. With the 10-year yield near its 2026 high and investors pricing no cut until late 2027, capital markets face a prolonged high-rate environment.
Blue Owl Eyes $30B Sale of Stack’s Asia Data Centers
Blue Owl Capital is exploring a $30B sale of Stack Infrastructure’s Asia Pacific data centers — potentially 2026’s largest private markets infrastructure exit.
30-Year Treasury Crosses 5%: What It Means for Mortgages and Markets
The 30-year Treasury yield closed at 5.025% on May 4, 2026 — crossing a key threshold. Here’s what the curve’s steepest gap since 2022 signals for rates, mortgages, and capital markets.
Apollo Raises $8.4B in 48 Hours as Private Credit Surges
Apollo closed Hybrid Value Fund III ($6.5B) and Accord Fund VII ($1.9B) in consecutive days. Ares set a Q1 fundraising record at $30B. Private credit is scaling at a historic pace.
Hubbell’s $3B NSI Deal Bets on America’s Grid Boom
Hubbell acquires NSI Industries for $3B, expanding its electrical infrastructure lineup as AI data centers and grid modernization drive record demand for power components.
Junk Bonds Beat Long Treasuries in 2026: What Credit Markets Signal
High yield bonds have delivered 9% one-year returns while long-duration Treasuries struggle near breakeven. Here’s what the 2026 credit divergence means.
Anthropic Could Raise $50 Billion at Near-$1 Trillion Value
Sources say Anthropic is fielding preemptive offers for a $40-50B round at $850-900B, backed by Google’s $40B pledge and Amazon’s $13B commitment, with one $5B buyer unable to get a meeting.
SpaceX Files for $75B IPO at $1.75 Trillion Valuation
SpaceX’s S-1 targets a $75B raise at a $1.75T valuation — nearly triple Saudi Aramco’s all-time IPO record. What it means for capital markets.
GLP-1 Startup Kailera Leads Biotech IPO Revival With $625M Deal
Kailera Therapeutics’ $625M GLP-1 IPO anchors a Q2 2026 healthcare listing wave, with Hemab Therapeutics, Avalyn Pharma, and peers all jumping 52-89% from their offer prices.